We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 19, 2024 – Stocks in this week’s article are Otter Tail Corp. (OTTR - Free Report) , OraSure Technologies Inc. (OSUR - Free Report) , BioMarin Pharmaceutical Inc. (BMRN - Free Report) and Regeneron Pharmaceuticals, Inc. (REGN - Free Report) .
Buy These 4 Low-Beta Stocks to Counter Market Volatility
The "fear gauge" on Wall Street has reached a two-month high due to a decline in U.S. stocks. However, encouraging retail sales highlights the economy’s strength. Overall, the market is likely to maintain its volatility, emphasizing the immediate necessity of constructing a portfolio comprising low-beta stocks. These securities are anticipated to generate substantial returns while offering a protective shield against unpredictable market conditions.
In this regard, stocks like Otter Tail Corp., OraSure Technologies Inc., BioMarin Pharmaceutical Inc. and Regeneron Pharmaceuticals, Inc. are worth betting on.
Understanding Beta
Beta measures the volatility or risk of a particular asset compared to the market. In other words, beta measures the extent of a security’s price movement relative to the market. In this article, we are considering the S&P 500 as the market.
If a stock has a beta of 1, then the price of the stock will move with the market. So, the stock is more volatile than the market if its beta is more than 1. In the same way, the stock is not as volatile as the market if its beta is less than 1.
For example, if the market offers a return of 20%, a stock with a beta of 3 will return 60%, which is overwhelming. Similarly, when the market slips 20%, the stock will sink 60%, which is devastating.
Here are four of the 11 stocks that qualified the screening:
Otter Tail Corporation is a leading player in electric utility and manufacturing businesses. Recovery of rate base investments continues to drive the firm. For 2024, Otter Tail has witnessed upward earnings estimate revisions in the past 60 days.
OraSure Technologies is a leading provider of specimen collection devices, point-of-care and home diagnostic tests. OraSure is focused on key strategic partnerships and internal innovation. OSUR has witnessed upward estimate revisions for its bottom line for 2024 over the past 60 days.
BioMarin Pharmaceutical, a prominent player in the field of biotechnology, specializes in the development of targeted therapies aimed at addressing the underlying causes of genetic conditions. FDA approval for VOXZOGO is a huge success for the company, which, along with other notable developments, will aid the top line.
Regeneron Pharmaceuticals is a prominent biotechnology company. With a robust business model, it engages in the discovery, development and commercialization of life-changing medications. The company is involved in improving its traditional drug development process.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron
For Immediate Release
Chicago, IL – January 19, 2024 – Stocks in this week’s article are Otter Tail Corp. (OTTR - Free Report) , OraSure Technologies Inc. (OSUR - Free Report) , BioMarin Pharmaceutical Inc. (BMRN - Free Report) and Regeneron Pharmaceuticals, Inc. (REGN - Free Report) .
Buy These 4 Low-Beta Stocks to Counter Market Volatility
The "fear gauge" on Wall Street has reached a two-month high due to a decline in U.S. stocks. However, encouraging retail sales highlights the economy’s strength. Overall, the market is likely to maintain its volatility, emphasizing the immediate necessity of constructing a portfolio comprising low-beta stocks. These securities are anticipated to generate substantial returns while offering a protective shield against unpredictable market conditions.
In this regard, stocks like Otter Tail Corp., OraSure Technologies Inc., BioMarin Pharmaceutical Inc. and Regeneron Pharmaceuticals, Inc. are worth betting on.
Understanding Beta
Beta measures the volatility or risk of a particular asset compared to the market. In other words, beta measures the extent of a security’s price movement relative to the market. In this article, we are considering the S&P 500 as the market.
If a stock has a beta of 1, then the price of the stock will move with the market. So, the stock is more volatile than the market if its beta is more than 1. In the same way, the stock is not as volatile as the market if its beta is less than 1.
For example, if the market offers a return of 20%, a stock with a beta of 3 will return 60%, which is overwhelming. Similarly, when the market slips 20%, the stock will sink 60%, which is devastating.
Here are four of the 11 stocks that qualified the screening:
Otter Tail Corporation is a leading player in electric utility and manufacturing businesses. Recovery of rate base investments continues to drive the firm. For 2024, Otter Tail has witnessed upward earnings estimate revisions in the past 60 days.
OraSure Technologies is a leading provider of specimen collection devices, point-of-care and home diagnostic tests. OraSure is focused on key strategic partnerships and internal innovation. OSUR has witnessed upward estimate revisions for its bottom line for 2024 over the past 60 days.
BioMarin Pharmaceutical, a prominent player in the field of biotechnology, specializes in the development of targeted therapies aimed at addressing the underlying causes of genetic conditions. FDA approval for VOXZOGO is a huge success for the company, which, along with other notable developments, will aid the top line.
Regeneron Pharmaceuticals is a prominent biotechnology company. With a robust business model, it engages in the discovery, development and commercialization of life-changing medications. The company is involved in improving its traditional drug development process.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2211917/buy-these-4-low-beta-stocks-to-counter-market-volatility
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.